Overview

* Savara reports Q3 net loss of $29.6 mln, compared to $24.2 mln loss last year

* Company strengthens balance sheet with $140 mln equity financing

Outlook

* Savara strengthens balance sheet to support potential MOLBREEVI launch

Result Drivers

* R&D EXPENSES - Increase in R&D expenses due to MOLBREEVI program activities, including regulatory and quality assurance costs

* ADMINISTRATIVE COSTS - Significant rise in general and administrative expenses due to strategic personnel additions and commercial activities

* BALANCE SHEET STRENGTHENING - $140 mln equity financing enhances financial position for MOLBREEVI commercialization

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.14

Q3 Net -$29.56

Income mln

Q3 -$30.26

Income mln

from

Operatio

ns

Q3 $30.26

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Savara Inc ( SVRA ) is $10.75, about 59.7% above its November 11 closing price of $4.33

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)